Solid Biosciences (SLDB) Current Deferred Revenue (2020 - 2022)

Solid Biosciences has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $6.2 million for Q1 2022.

• Current Deferred Revenue for Q1 2022 came in at $6.2 million, down 65.07% year-over-year; the trailing twelve-month figure through Mar 2022 was $6.2 million (down 65.07% YoY), and the FY2021 annual result was $8.1 million, down 61.0% from the prior year.
• Current Deferred Revenue came in at $6.2 million for Q1 2022 at Solid Biosciences, down from $8.1 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $20.7 million in Q4 2020 to a low of $6.2 million in Q1 2022.
• The 3-year median for Current Deferred Revenue is $11.6 million (2021), against an average of $12.6 million.
• Across the five-year window, Current Deferred Revenue sank 61.0% in 2021 and plunged 65.07% in 2022, its largest moves.
• Solid Biosciences' Current Deferred Revenue stood at $20.7 million in 2020, then tumbled by 61.0% to $8.1 million in 2021, then retreated by 23.64% to $6.2 million in 2022.
• The last three Current Deferred Revenue figures came in at $6.2 million (Q1 2022), $8.1 million (Q4 2021), and $8.9 million (Q3 2021), per Business Quant data.